 CAMBRIDGE, Mass. LAUSANNE, Switzerland--BUSINESS WIRE--Seres Therapeutics, Inc. Nasdaq: MCRB, a leading microbiome therapeutics company, announced today that it has entered into an agreement with Nestlé Health Science to jointly commercialize SER-109, Seres investigational oral microbiome therapeutic for recurrent Clostridioides difficile infection CDI, in the United States U.S. and Canada. If approved, SER-109 would become the first-ever FDA-approved microbiome therapeutic. Under th 